// App-Quantinova.ai

OP0255 (2022) : BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: 16-WEEK EFFICACY & SAFETY FROM BE COMPLETE, A PHASE 3, MULTICENTRE, RANDOMISED PLACEBO-CONTROLLED STUDY

Researchers

Presenter

  • J. F. Merola

Principal Investigators

  • I. McInnes

  • C. T. Ritchlin

  • P. J. Mease

  • R. B. M. Landew

  • A. Asahina

  • Y. Tanaka

  • R. B. Warren

  • L. Gossec

  • D. D. Gladman

  • F. Behrens

  • B. Ink

  • D. Assudani

  • R. Bajracharya

  • J. Coarse

  • L. Coates

Medical Centers

  • Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, Boston, United States of America

  • University of Glasgow, Institute of Infection Immunity and Inflammation, Glasgow, United Kingdom

  • University of Rochester, Department of Medicine, Rochester, United States of America

  • University of Washington, Swedish Medical Center and Providence St. Joseph Health, Seattle, United States of America

  • Amsterdam Rheumatology & Clinical Immunology Center, Department of Clinical Immunology & Rheumatology, Amsterdam, Netherlands

  • Zuyderland MC, N/A, Heerlen, Netherlands

  • Keio University School of Medicine, Department of Urology, Tokyo, Japan

  • University of Occupational and Environmental Health, Japan, The second department on internal medicine, Kitakyusyu, Japan

  • University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom

  • Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France

  • University of Toronto, Krembil Research Institute, Toronto, Canada

  • University Health Network, Schroeder Arthritis Institute, Toronto, Canada

  • Goethe University, Rheumatology and Fraunhofer Institute Translational Medicine and Pharmacology ITMP, Frankfurt, Germany

  • UCB Pharma, Slough, UK Slough United Kingdom

  • UCB Pharma, Raleigh, United States of America

  • Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Oxford, United Kingdom

  • Oxford University Hospitals NHS Trust Biomedical Research Centre, Oxford, United Kingdom

Locations

  • United States

  • United Kingdom

  • Netherlands

  • Japan

  • France

  • Canada

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Musculoskeletal

  • Dermatology

Disease

  • Psoriatic arthritis

Biomarkers

  • N/A

Drug/Treatment

  • bimekizumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Open Label

  • Multicenteric

  • Controlled

Phase

  • III

Study Id's

  • NCT03896581

Sponsors

  • UCB

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved